Brussels · May 12, 2026 · Breaking Report | ForensicTimes.com | Public Health · EU Policy · Pharmaceutical Industry
Table of Contents
- The Deal: What Was Agreed on May 12
- The Crisis That Made the Law Necessary
- What the Critical Medicines Act Actually Does
- The Pharmaceutical Package: A Broader Reform Beyond Shortages
- Forensic Analysis: How Drug Shortages Happen and Why They Kill
- Criminal Psychology of Supply Chain Failure: Who Profits from Scarcity
- Law and Legal Implications: Obligations, Penalties and the 2028 Timeline
- Global Context: Europe’s Dependence on Asia and the Geopolitics of Medicine
- Investigation: What Remains Unresolved
- The Patient at the Counter
The Deal: What Was Agreed on May 12
On Tuesday, May 12, 2026, the Cyprus presidency of the EU Council and the European Parliament’s negotiators reached a provisional agreement on the Critical Medicines Act — a standalone regulation designed to address the structural vulnerabilities in Europe’s pharmaceutical supply chains that have produced repeated, severe shortages of essential drugs in recent years.
The agreement was announced by Cypriot Health Minister Neophytos Charalambides, who described it as a practical step toward ensuring citizens no longer face uncertainty when seeking essential treatments. “Patients should not have to worry about whether critical medicines such as antibiotics will be available at their pharmacy or hospital,” the EU Council’s press release stated. The provisional agreement now requires formal endorsement from both institutions before entering into force — a procedural step expected in the coming months.
The CMA is a component of the broader EU Pharmaceutical Package, itself the most comprehensive overhaul of European pharmaceutical legislation since Directive 2001/83/EC was adopted more than two decades ago. The pharmaceutical package’s main regulation and directive reached political agreement on December 11, 2025, with compromise texts published in March 2026. The Critical Medicines Act addresses the specific and acute problem of supply shortages — a dimension of the broader package elevated to standalone regulatory status precisely because of the urgency of recent European shortage experiences.
MEP Vlad Vasile-Voiculescu of Renew Europe, who led the Parliament’s negotiating team, described the agreement as “a historic step towards making sure Europeans can access the medicines they need, when they need them.” He added: “We have learned from recent crises that no Member State can face shortages alone. By strengthening cooperation, and supporting production in Europe, we are building a stronger and more secure European Health Union for all citizens.”
The Crisis That Made the Law Necessary
The Critical Medicines Act was not conceived in abstract policy planning. It was forced into existence by a series of visible, documented, and politically embarrassing failures in European pharmaceutical supply that accumulated across the period from 2020 to 2024 and showed no sign of resolving through market mechanisms alone.
The most acute phase began in late 2022 and extended through 2023, when shortages of amoxicillin — the most widely prescribed antibiotic in Europe — hit pharmacies and hospitals simultaneously across multiple member states. Paediatric formulations were the first to disappear, leaving parents and clinicians unable to treat common bacterial infections in children. The shortage was not caused by any single factory failure or trade disruption. It reflected a structural condition: approximately 60 to 80 percent of the active pharmaceutical ingredients used in European drug manufacturing are produced in China and India, with production concentrated in a small number of facilities. Any disruption to that concentrated production — whether from factory closure, regulatory action, raw material shortage, or geopolitical friction — propagates immediately across all the European manufacturers who source from those facilities.
Paracetamol for children, metformin for diabetes management, amoxicillin for bacterial infections, and insulin formulations all experienced supply constraints across this period. Cancer patients reported delays in chemotherapy regimens. Hospitals implemented rationing protocols for drugs that, in a functioning supply environment, they had never had to ration. The European Medicines Agency’s shortage tracking data showed a steep increase in the number of medicines officially classified as in shortage from 2020 onward, with the curve accelerating rather than stabilising.
The COVID-19 pandemic was the catalytic event that made the political case for legislative intervention unanswerable. The global competition for PPE, ventilators, and eventually vaccines during 2020 demonstrated, in the most visceral possible way, that supply chains optimised for efficiency rather than resilience become catastrophic liabilities during a crisis. The Critical Medicines Act is, in its deepest architecture, a post-pandemic reckoning with the risk that a continent of 450 million people depends for its most essential medicines on production capacity located primarily outside its borders.
What the Critical Medicines Act Actually Does
The Critical Medicines Act introduces a series of interlocking mechanisms designed to address the shortage problem from multiple angles simultaneously — the supply chain, the procurement architecture, and the manufacturing base.
The first and most foundational mechanism is the establishment of a formal EU-wide list of critical medicinal products, maintained by the European Commission on the basis of input from national competent authorities. Medicines on this list — antibiotics, insulin, cancer drugs, and other therapeutics whose unavailability would constitute a public health emergency — become subject to enhanced monitoring, governance, and the full suite of obligations created by the CMA. The list is not static. It is intended to be updated as the risk landscape changes, with the Commission empowered to add or remove products based on ongoing vulnerability assessments of their supply chains.
The second mechanism is the resilience requirement in public procurement. The provisional agreement introduces an obligation for public contracting authorities — hospitals, national health services, regional procurement bodies — to apply resilience-related requirements when procuring critical medicines. In practical terms, this means that price alone can no longer be the primary or sole criterion in public tenders for critical drugs. Procurement processes must account for the geographic diversification of the supplier’s production base, the robustness of its supply chain, and its capacity to maintain supply under stress conditions. This is a structural shift from the decades-long European procurement norm of selecting the cheapest available supplier regardless of supply chain resilience.
The third mechanism is collective procurement. The new regulation allows EU member states to join forces when procuring critical medicines and medicines of common interest — pooling their market power to negotiate better terms and diversify supply. Crucially, the negotiators reduced the threshold of member states required to submit a request to the Commission to procure on their behalf from nine to five, making collective procurement a practical option for smaller coalitions of willing states rather than a mechanism requiring near-universal consensus.
The fourth mechanism is EU manufacturing incentives. The regulation provides flexibility for contracting authorities in implementing an “EU preference” approach in procurement — giving preference to medicines manufactured within the EU or from EU-based active pharmaceutical ingredient production, as a mechanism for incentivising the onshoring of production that has migrated to Asia over the past three decades. This is legally sensitive in the context of EU internal market rules and WTO commitments, and the “flexibility” language reflects the difficulty of squaring the incentive objective with existing trade law obligations.
The Pharmaceutical Package: A Broader Reform Beyond Shortages
The Critical Medicines Act does not stand alone. It is part of the EU Pharmaceutical Package, described by the European Medicines Agency as the most significant overhaul of the EU regulatory framework for medicines in over two decades. The package replaces the longstanding Community Code (Directive 2001/83/EC), the EMA Regulation (Regulation 726/2004), the Orphan Medicinal Products Regulation, and related legislation — effectively rewriting the foundational legal architecture of how medicines are developed, authorised, and made available across the EU.
The broader package addresses dimensions of pharmaceutical governance that go well beyond supply shortages. It introduces mandatory shortage prevention plans for all prescription medicines and critical medicinal products — requiring marketing authorisation holders to conduct regular risk assessments of their supply chains and establish mitigation measures before shortages occur, rather than responding to them after the fact. It strengthens notification obligations, requiring advance notice of supply disruptions of two years or longer, giving authorities time to manage the transition rather than scrambling in real time.
On innovation, the package introduces a transferable exclusivity voucher for antimicrobials — a tradable financial incentive for companies that develop new antibiotics targeting multi-drug resistant organisms, which represent one of the most severe long-term public health threats in Europe and globally. The voucher grants one additional year of regulatory data protection, which can be sold to another company, creating a market-based mechanism to make antibiotic development financially viable for the pharmaceutical industry at a time when the conventional drug development economic model makes antibiotics structurally unattractive investments.
The reform also restructures the EMA’s scientific committee architecture, creating stronger coordination between the central regulatory body and national competent authorities, and introduces regulatory sandboxes — controlled environments in which manufacturers can develop new technologies (including AI-integrated manufacturing, continuous processing, and novel drug delivery systems) within a supervised framework before those approaches are incorporated into standard regulatory procedures.
Forensic Analysis: How Drug Shortages Happen and Why They Kill
Understanding the Critical Medicines Act requires understanding the precise mechanisms by which pharmaceutical supply chains fail — mechanisms that are structural, documented, and in many cases predictable, but that the previous regulatory framework had no adequate tools to prevent or manage.
Active pharmaceutical ingredients — the chemically active compounds from which drugs are manufactured — are the foundation of the supply chain’s vulnerability. For the majority of generic medicines used in European healthcare, API production is concentrated in a small number of facilities in India and China, where lower production costs and regulatory environments allowed large-scale manufacturing to consolidate over a period of three to four decades. A single factory in Gujarat or Shandong may supply APIs to dozens of European manufacturers simultaneously. When that factory encounters a regulatory enforcement action, a fire, an environmental inspection, a raw material shortage, or — as during COVID — a logistics disruption, every downstream manufacturer is affected simultaneously. The concentration of production that makes API supply economically efficient makes it catastrophically fragile under stress.
The second mechanism is the commercial logic of generic pharmaceutical pricing. Generic drugs are, by design, low-margin products. Competition between manufacturers drives prices toward the minimum sustainable level. Manufacturers who cannot achieve the minimum sustainable price exit the market. Over time, this produces market consolidation — fewer manufacturers supplying each product — which further concentrates the supply chain’s vulnerability. For some critical generic medicines, the European market has as few as two or three active manufacturers globally. The loss of one is not a disruption. It is a crisis.
The third mechanism is the absence, until the CMA, of any requirement for manufacturers to maintain buffer stocks or to notify authorities before discontinuing supply. A manufacturer who decides to exit the market for an unprofitable generic antibiotic was, until the pharmaceutical package’s notification obligations, under no legal obligation to tell anyone in advance. The first signal that European pharmacies received of a looming shortage was often the empty shelf itself.
The human cost of these failures is documented and material. Drug shortages in hospital settings have been associated with medication errors, as clinicians substitute unfamiliar alternatives for standard drugs whose doses and side effect profiles they know well. Patients with chronic conditions who depend on stable medication regimens experience adverse outcomes when their regular medication is unavailable and substitution is required. Cancer patients whose chemotherapy protocols are disrupted face both the direct medical consequences of treatment delay and the psychological consequences of uncertainty about whether their treatment will be available next month.
Criminal Psychology of Supply Chain Failure: Who Profits from Scarcity
The pharmaceutical supply shortage is not merely a logistics problem. It is also a documented arena for criminal exploitation. Medicine shortages create black markets. They create conditions in which counterfeit, substandard, or falsified medicines find buyers who would otherwise never purchase outside licensed pharmacy channels. They create opportunities for fraud in public procurement that the conventional competitive tendering environment does not produce.
During the COVID-19 pandemic, Europol and the Medicines and Healthcare products Regulatory Agency in the UK documented a significant surge in falsified medicines and medical countermeasures entering European supply chains as legitimate channels were overwhelmed and desperate buyers — individuals, hospitals, and governments — purchased from unverified sources. The same dynamic operates, at smaller scale, during every significant shortage of a high-demand medicine.
The economic logic is straightforward. A shortage of amoxicillin that drives the legitimate market price up by a factor of three or four creates both the motive and the opportunity for criminal actors who can supply a product at that price regardless of its quality or authenticity. The criminal economy of medicine fraud operates exactly as the criminal economy of any scarce commodity — shortages are not merely problems to be solved but opportunities to be exploited by actors who are not bound by the supply constraints that limit legitimate manufacturers.
The Critical Medicines Act’s transparency mechanisms — the mandatory shortage prevention plans, the advance notification obligations, the EU-level monitoring through the EMA’s Medicines Shortages Steering Group — address this dimension indirectly. By creating earlier warning systems that allow authorities to anticipate shortages and act to prevent them, the Act reduces the periods of acute scarcity during which criminal exploitation is most profitable. Preventing the shortage is also, forensically, the most effective counterfeit medicine prevention strategy available.
Law and Legal Implications: Obligations, Penalties and the 2028 Timeline
The Critical Medicines Act, once formally adopted, creates binding legal obligations across multiple categories of actor in the pharmaceutical supply chain. The most significant new obligations fall on marketing authorisation holders — the companies that hold the regulatory approval for a medicine and are therefore legally responsible for its supply.
Under the pharmaceutical package’s shortage provisions, MAHs of prescription medicines and critical medicinal products must establish and maintain mandatory shortage prevention plans. These plans must be based on regular risk assessments of the supply chain — identifying the points of concentration, the alternative sourcing options, the buffer stock levels, and the escalation protocols for supply disruptions. They are not symbolic documents. They are operational planning requirements that will be assessed by national competent authorities and the EMA as part of ongoing regulatory compliance.
The notification obligations create a parallel legal dimension. MAHs must inform competent authorities of any temporary or permanent supply disruption. Where a disruption is expected to last for two years or more — a permanent market exit, in practical terms — advance notice of at least six months must be provided. This gives regulators, procurement authorities, and alternative manufacturers the time to respond before the shortage affects patients. Failure to comply with notification obligations will constitute a regulatory violation with consequences that the pharmaceutical package specifies in its enforcement provisions.
The timeline for implementation is precise and sequential. Both the CMA and the broader pharmaceutical package regulation will enter into force on the twentieth day following their publication in the Official Journal of the EU. The regulation then becomes applicable 24 months after entry into force — meaning that for formal adoption expected in late 2026, the obligations will apply from approximately 2028. Member states have the same 24-month period to transpose the directive into national law. The two-year implementation window is intended to give manufacturers, regulatory authorities, and national health systems time to adapt their procedures, documentation, and supply chain management to the new requirements.
Formal adoption is expected imminently. The compromise texts are, per the legal consensus among pharmaceutical law practitioners, now stable enough that the specific obligations can be planned against. For pharmaceutical companies operating in Europe, the compliance timeline has effectively begun.
Global Context: Europe’s Dependence on Asia and the Geopolitics of Medicine
The Critical Medicines Act is, in its geopolitical dimension, a pharmaceutical sovereignty initiative — an attempt to reduce Europe’s strategic dependence on production capacity concentrated in countries whose political relationship with the EU is either adversarial (in the case of China) or whose domestic regulatory environment can produce sudden supply disruptions (in the case of India).
The scale of that dependence is documented and significant. Despite the EU pharmaceutical sector employing approximately 900,000 people and being one of the continent’s largest export industries by value, the production of active pharmaceutical ingredients has migrated extensively outside Europe over the past three decades. For critical generic medicines — the antibiotics, painkillers, diabetes drugs, and basic hospital medicines that healthcare systems depend on daily — the concentration of API production in Asia is particularly acute. Some estimates suggest that 60 to 80 percent of APIs used in European manufacturing are sourced from outside Europe, with China and India accounting for the majority.
This dependence has specific geopolitical implications in the current environment. The US-Israel war on Iran and its closure of the Strait of Hormuz has demonstrated, since February 2026, that geopolitical events can disrupt global shipping and energy supply chains with immediate economic consequences across Europe. A similar geopolitical disruption affecting pharmaceutical supply chains — whether from a Taiwan Strait crisis affecting Chinese API production, from US-China trade friction disrupting Indian generic manufacturers who depend on Chinese APIs, or from any number of other scenarios — would produce medicine shortages that dwarf what Europe experienced with amoxicillin in 2022–2023.
The €5 billion in projected EU funding for pharmaceutical manufacturing onshoring that the CMA framework enables is, in this context, not merely a health policy investment. It is a strategic infrastructure investment in the same category as the European Defence Industry Programme and the semiconductor sovereignty initiatives that have accelerated since 2022. Medicine is a strategic dependency. The Critical Medicines Act is the legislative instrument through which Europe is beginning to treat it as one.
Investigation: What Remains Unresolved
The provisional agreement reached on May 12 resolves the legislative question — what the law says — but leaves open a range of implementation questions whose answers will determine whether the CMA produces the outcomes its negotiators intended.
The “EU preference” mechanism in public procurement is the most legally contested element. Giving preference to EU-manufactured medicines in public tenders may conflict with WTO Agreement on Government Procurement obligations and with EU internal market principles regarding free movement of goods. The “flexibility” language in the agreement reflects a deliberate deferral of this tension rather than its resolution. How national contracting authorities implement the preference principle, and whether any procurement decision favouring EU manufacturers over cheaper Asian-sourced alternatives survives legal challenge, will be tested in the first years of the regulation’s application.
The threshold reduction for collective procurement — from nine to five member states — increases the mechanism’s usability but does not guarantee its use. Member states have historically been reluctant to surrender national procurement autonomy, particularly for medicines where pricing negotiations with pharmaceutical companies are considered commercially sensitive. Whether five member states will in practice coordinate sufficiently to trigger the collective procurement mechanism, and whether the Commission’s management of that process will be effective, will depend on political will and institutional capacity that the law creates the conditions for but cannot mandate.
The antimicrobial resistance dimension of the broader package — the transferable exclusivity voucher — is an innovative financial mechanism whose real-world effect depends on whether the voucher’s value is sufficient to change pharmaceutical companies’ R&D investment decisions. The expected value of a TEV has been estimated at several hundred million euros by industry analysts. Whether that is sufficient to make new antibiotic development commercially viable, given the regulatory and clinical development costs of a new antimicrobial, is a question that will not be answered until the first TEVs are awarded and the market for trading them matures.
Finally, the 2028 implementation date means that the obligations created by today’s agreement will not be in force for approximately two years. In the interim, the structural vulnerabilities that produced the amoxicillin shortage, the paracetamol rationing, and the insulin supply constraints remain entirely unaddressed by any binding legal requirement. A severe shortage event in the 2026–2028 window would be managed under the same pre-CMA framework that failed to prevent previous ones.
The Patient at the Counter
The Critical Medicines Act will not be visible to the patient who walks to a pharmacy to collect a prescription for their child’s ear infection. It will not appear on the packaging of the antibiotic they are dispensed. It will not be mentioned by the pharmacist who hands it over. If it works as intended, the only evidence of its existence will be the absence of a conversation that has been happening in pharmacies across Europe for several years: “I’m sorry, we don’t have that in stock. I don’t know when we will.”
That negative evidence — the conversation that does not happen, the shelf that is not empty, the prescription that is filled without substitution or delay — is what the legislation is designed to produce. It is the least visible form of policy success: the crisis that did not occur, the patient who received their medication, the cancer treatment that was not delayed, the diabetic whose insulin was available.
Whether the CMA delivers that outcome depends on implementation decisions not yet made, enforcement capacity not yet demonstrated, and manufacturing investments not yet completed. The law, as of May 12, 2026, is an agreement on paper. The pharmaceutical supply chains it is designed to reform are still concentrated in the same geographic locations, still governed by the same commercial logic, and still vulnerable to the same disruptions that emptied the shelves in 2022 and 2023.
The deal was struck today. The work begins in 2028. The patient at the counter is watching the shelf.
ForensicTimes · forensictimes.com · Investigative Journalism on Crime, Justice & Forensic Science · © 2026 ForensicTimes. All rights reserved.
